Inside Information: Other news releases

Aliko Scientific Provides a financial update following the publication of its FY 2025 results and reaffirms its business momentum

Paris, France – August 24, 2026 – 6:00 pm CEST – ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today provides additional financial details following the publication, on July 30, 2026, of its 2025 annual results and its 2025 Annual Financial Report, while reaffirming its business momentum. This information pertains to the statutory auditors’ reports, the Company’s financial position and cash flow outlook supported by the business strategy, as well as the schedule for its next Annual General Meeting.

Francesco Trisolini, Chief Executive Officer of Aliko Scientific, stated: “Since year-end we have progressively strengthened the Group’s financial position, notably through the issuance of convertible notes subscribed by long-term investors and through active management of our historical liabilities, costs and working capital requirements. The Board of Directors has carried out a detailed review of our financial position and has approved an updated cash-flow plan, including upside and downside scenarios. Based on this plan and the measures already implemented, management considers that the Company has the resources necessary to meet its forecast financing requirements and continue its operations for at least the next twelve months. At the same time, we remain focused on the commercial development of our integrated oncology diagnostics platform and on progressively increasing the recurring component of our business.”

Information from the auditors’ reports on going concern

The auditors’ reports on the annual and consolidated financial statements for the financial year ended December 31, 2025, included a material uncertainty related to going concern. The statutory financial statements were audited with an unqualified opinion. The consolidated financial statements were audited with a qualified opinion regarding the existence and valuation of inventory recorded in the amount of €730,016 (due to the change of local auditors following year end).

On July 16, 2026, the Board of Directors, which acknowledged the considerations raised by the statutory auditors, reviewed the financial position of the Company and the Group, the consolidated cash-flow forecast, the commercial outlook, the evolution and maturity of liabilities, and the financing obtained after the financial year-end.

As part of this review, the Board notably examined an updated cash-flow plan designed to assess the Company's financing requirements on prudent assumptions. The Board also considered the commercial elements supporting the plan, the recurring nature of part of the Group's activities, the measures implemented to manage historical liabilities, the control of costs and working capital requirements, and the financial support received from existing shareholders.

Following its review, the Board of Directors unanimously approved the updated cash-flow plan and its underlying assumptions and concluded that the Company and the Group are able to continue as a going concern.

Accordingly, management considers that the use of the going-concern basis remains appropriate.

The material uncertainty related to going concern identified by the statutory auditors is described in their reports included in the 2025 Annual Financial Report.

Improvement of the financial position, indebtedness and financing horizon

As written in the 2025 Annual Financial Report, as of December 31, 2025, the Group’s consolidated cash and cash equivalents amounted to €1.03 million. As of the same date, total liabilities (including working capital liabilities) totaled €5.74 million. The Group actively manages the maturity of these liabilitiesthrough regular monitoring of cash inflows and outflows, contractual maturities and working capital requirements, together with repayment schedules and settlement agreements with its principal creditors.

As of the date of this press release, management estimates a reduction of the liabilities presented in the 2025 Annual Financial Report by approximately €700k since the beginning of 2026. This reduction in debt should be distinguished from cost-cutting measures which are being implemented across the entire Group. More details will be available in the 2026 Half-year Financial Report.

Convertible note financing completed after year-end

After the end of the fiscal year, in July 2026, the Company raised a net amount of approximately €688k through the issuance of three convertible notes with a total nominal price of €722.5k to three existing investors.

The notes are non-interest-bearing, unsecured, unsubordinated, and have a maturity of 4 months from the issuance on June 26, 2026. They can be converted at maturity or earlier at the discretion of the Company at a conversion price of €1.5 per share. The Company and the relevant noteholder may mutually agree to repayment in cash.

The issuance of the notes was carried out pursuant to the 12th resolution of the Company's shareholders' meeting held on December 19, 2025, and did not require the publication of a prospectus under the applicable regulations.

In July 2026 the funds have been fully paid into the Company's bank accounts and strengthen the Group's available liquidity. They have been incorporated into the updated cash-flow plan reviewed by the Board of Directors.

Potential dilution for an existing shareholder

Based on the 15,843,148 shares outstanding and the equity as at December 31, 2025 (i.e. €26,021,806), the theoretical impact on equity per share would be:

Based on the 15,843,148 shares outstanding and the consolidated equity as of December 31, 2025 (i.e. €19,131,415), the theoretical impact on equity per share would be:

Based on 15,825,248 shares existing before conversion, the impact of the full conversion of the bonds on a shareholder holding 1% of the Company's share capital would be as follows:

2026 outlook: pursuit of industrial and commercial rollout of the integrated oncology diagnostics platform

Building on the momentum achieved in 2025, the Company intends to continue the industrial and commercial rollout of its integrated oncology diagnostics platform, which combines standardized sample preparation, liquid-based cytology, automated FISH analysis, digital imaging, software, consumables and related services.

This momentum is supported, in particular, by several key milestones achieved in 2025 and 2026, including the launch of Urine24, the exclusive distribution agreement signed with Menarini Diagnostics, the MoU signed with Cellay for the US market and the MoU signed with BioBrasil to produce its own FISH reagents and the two-distribution agreement signed in July 2026 for Romania and Saudi Arabia.

Schedule for the Annual General Meeting

The Company has obtained an extension from the Court to hold its Annual General Meeting by October 30, 2026. The final date and the meeting notice documents will be published in the Bulletin des Annonces Légales Obligatoires (BALO) and made available on the Company’s website within the applicable legal deadlines.

---------------------

About ALIKO SCIENTIFIC

Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC’s mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of excellence in oncology.

For more information, visit: www.alikoscientific.com

About IKONISYS

Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes.

For more information, visit: www.ikonisys.com

Contacts

Ikonisys
Alessandro Mauri
CFO
investors@ikonisys.com

NewCap
Louis-Victor Delouvrier/Alexandre Massias
Investor Relations
Ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 94

NewCap
Nicolas Mérigeau
Media Relations
Ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98

Disclaimer

This press release contains forward-looking statements about the Company’s prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as “believe”, “aim to”, “expect”, “intend”, “estimate”, “believe”, “should”, “could”, “would” or “will” or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company’s intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.

Notes

1. Dilution takes into account the exercise of all outstanding dilutive instruments likely to result in the issuance of a maximum indicative number of 897,043 new shares (including the issuance of 500,000 related to the completion of the acquisition of Hospitex International).